Abstract: Nanoparticle technology is being incorporated into many areas of molecular science and biomedicine. Because nanoparticles are small enough to enter almost all areas of the body, including the circulatory system and cells, they have been and continue to be exploited for basic biomedical research as well as clinical diagnostic and therapeutic applications. For example, nanoparticles hold great promise for enabling gene therapy to reach its full potential by facilitating targeted delivery of DNA into tissues and cells. Substantial progress has been made in binding DNA to nanoparticles and controlling the behavior of these complexes. In this article, we review research on binding DNAs to nanoparticles as well as our latest study on non-viral gene delivery using polyethylenimine-coated magnetic nanoparticles.
Introduction
Nanotechnology describes the creation and utilization of materials, devices, and systems through the control of nanometer-sized materials and their application to physics, chemistry, biology, engineering, materials science, medicine, and other endeavors. In particular, intensive efforts are in progress to develop nanomaterials for medical use as agents that can be targeted to specific organs, tissues, and cells. For example, magnetic nanoparticles (MNPs) are being used clinically as contrast agents for magnetic resonance imaging (MRI) ( Table 1) . MRI is a noninvasive technique that can provide real-time high-resolution soft tissue information [1, 2] . MRI image quality can be further improved by utilizing contrast agents that alter proton relaxation rates [3] [4] [5] [6] [7] [8] . MNP-based drug delivery systems (DDS) [9] [10] [11] , and treatments of hyperthermia [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] , using MNPs have been studied for over a decade. Furthermore, researchers have reported that MNPs have been useful in hyperthermic treatment for various cancers in vivo [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . Nanotechnology-based anti-cancer agent DDS have already been approved, such as pegylated liposomal doxorubicin (DOXIL) for ovarian cancer [32] [33] [34] [35] [36] [37] . MNPs have been used effectively as transfection reagents for introducing nucleic acids (plasmids or siRNAs) [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] , or viruses (retrovirus, or adenovirus) [44, [54] [55] [56] into cells. Our own research is focused on MNP-mediated gene delivery systems (called as "Magnetofection"). 
Gene Delivery
Gene delivery techniques efficiently introduce a gene of interest in order to express its encoded protein in a suitable host or host cell. Currently, there are three primary gene delivery systems that employ viral vectors (retroviruses and adenoviruses), nucleic acid electroporation, and nucleic acid transfection. These systems vary in efficacy (Table 2) . Gene delivery by viral vectors can be highly efficient (80-90%) but may insert viral vector nucleic acid sequences into the host genome, potentially causing unwelcome effects, such as inappropriate expression of deleterious genes. Electroporation is also a highly efficient technique for introducing foreign genes into a host (50-70%); however, half of the recipient cells die due to the electrical stimulation. Transfection reagents do not efficiently deliver nucleic acids into cells (20-30%); however, cell viability is largely preserved and the method is safe enough for clinical use. Therefore, this method holds relatively more promise for medical applications, provided that its efficiency can be improved. MNPs are already in use by basic researchers to increase transfection efficiencies of cultured cells. Thus, MNP-nucleic acid complexes are added to cell culture media and then onto the cell surface by applying a magnetic force (Figure 1 ). [62, 63] . However, these nanoparticles are highly toxic to cells, limiting their use for in vivo, and in vitro biomedical applications [64] [65] [66] [67] . However, iron oxides such as magnetite (Fe 3 O 4 ) and maghemite (γ-Fe 2 O 3 ), in particular, possess high magnetic moments, are relatively safe, and currently in clinical use as MRI contrast agents [57] [58] [59] [60] [61] . These iron oxide based-magnetic materials are also suitable for biomedical applications. Fe 3+ is widely dispersed in the human body so leaching of this metal ion from nanoparticles should not reach toxic concentrations [68, 69] . As a result, maghemite is a popular choice for MNPs used biomedical applications. It is very important to modify the surface of MNPs so that they can be used for biomedical applications. Thus, MNPs are coated with compounds such as natural polymers (proteins and carbohydrates) [70] [71] [72] [73] [74] [75] , synthetic organic polymers (polyethylene glycol), polyvinyl alcohol, poly-L-lactic acid) [72, [76] [77] [78] , silica [79] , and gold [80, 81] . These surface coating agents prevent nanoparticle agglomeration, cytotoxicity, and add functionality. MNPs agglomerate readily in aqueous solutions around pH 7 [82] , and it is difficult to control the properties and amounts of agglomerated MNPs. The greater toxicity of MNPs compared to those of microparticles can be attributed to their high surface to volume ratio [83] . Coating agents prevent the leaching of potentially toxic components from MNPs. In fact, the cytotoxicity of uncoated NiFeO 4 MNPs is dramatically decreased by coating with cationic polymer, polyethylenimine (PEI) [84] [85] [86] . PEI, a cationic polymer, is widely used for nucleic acid transfection [87] [88] [89] and also serves as a nanoparticle dispersant [90] 
Cell Transplantation Therapy Using MNPs
Autologous cell transplantation has been widely used in the clinic for decades. Delivering therapeutic genes to patients using their own cells avoids using immunosuppressive drugs. We reasoned, therefore, that a non-viral gene delivery system using iron oxide-based MNPs could provide a powerful tool for next-generation therapies. Gene delivery using MNPs has been successful for delivering nucleic acids into living cells with high efficiency and low cytotoxicity [38, 41, 42, [44] [45] [46] 48, 49, 51, 54, 55] . Currently, there are several methods for inducing cellular differentiation.
One of these methods, termed direct reprogramming, or direct conversion, has successfully yielded induced cardiomyocytes, induced neurons, reprogrammed pancreatic β cells, and induced pluripotent stem cells (iPSCs) [91] [92] [93] [94] [95] . Direct reprogramming represents a more straightforward strategy to treat diseases involving loss of function by specific cell populations compared to approaches requiring an Here we briefly describe the magnetofection [96] , and our latest study concerning non-viral gene delivery using deacylated polyethylenimine coated MNPs. 
Gene Delivery Using MNPs and Magnetic Force
The mechanism of magnetofection is similar to using transfection reagents (Lipofectamine 2000, FuGENE HD, and PEI). The only difference is that the plasmids form complexes with cationic polymer-coated MNPs (called as "Magnetoplex") [42, 48, [97] [98] [99] (Figure 3 ). Figure 3 shows the two difference techniques. The behavior of magnetoplex is readily controlled by magnetic force. Upon binding to the cell surface they are taken up by endocytosis [51, 100, 101] . Thus, the transfection efficiency was increased.
Figure 3.
Gene delivery systems using a transfection reagent (cationic polymer) and MNPs: (A) Gene delivery system using transfection reagent. The polyplex moves randomly in culture medium; (B) Magnetofection system. The magnetoplex only moves to the cell surface.
Many researchers have described magnetofection methods (Table 3) . They modified the surface of iron oxide-based MNPs to increase transfection efficiency and reduce cytotoxicity. To achieve this, some investigators selected coating agents such as anionic surfactants (oleic acid, lauroyl sarcosinate) [ [54] [55] [56] . These coating agents are often used in conjunction with PEI. PEI is a well-known cationic gene carrier with high transfection efficiency. However, the high toxicity, depended on its molecular weight, has limited its use as a potential gene carrier. Thus, the PEI was modified to increase transfection efficiency, and decrease cytotoxicity [88, 106] [108, 109] The highest transfection efficiencies have been achieved using 25,000 molecular weight linear PEI [89] . However, PEI cytotoxicity due to its acyl groups has been described [88] . Therefore, our group focused on commercial deacylated PEI (Polyethylenimine "Max" (PEI "Max"), Polysciences Inc.) as an MNP (γ-Fe 2 O 3 , d = 70 nm, CIK NanoTek) coating agent.
Deacylated polyethylenimine (linear, 25,000 molecular weight) is built from the same polymer backbone as the popular linear polyethylenimine, and possesses high cationic reactivity. PEI "Max"-coated MNPs (PEI max-MNPs) are stable in deionized water, and positively charged. Thus, PEI max-MNPs electrostatically bind to plasmids. We attempted to introduce the green fluorescent protein (GFP) gene into a mouse embryonic carcinoma cell line, P19CL6 using PEI max-MNPs, and succeeded in establishing a highly efficient and low cytotoxic gene delivery system [107] . Furthermore, we applied this system to human fetal lung-derived fibroblasts (TIG-1 cells) using sixwell plates. Using MNPs, the transfected gene's expression level increased 2-to 4-fold under optimum conditions (Figure 4 , unpublished data). Furthermore, to assess whether the multiple plasmids were expressed in a single cell, we attempt to induce the expression of three fluorescent proteins GFP, cyan fluorescent protein (CFP), and yellow fluorescent protein (YFP). Most cells expressed these three proteins ( Figure 5 , unpublished data) indicating that gene delivery using MNPs could introduce and allow expression of multiple genes in a single cell. 
Conclusions
The great promise of gene therapy for treating devastating, incurable diseases has yet to be realized. Less toxic and more efficient systems will be required, and robust research efforts in this regard are currently underway. Rapid advances have been made in adapting nanoparticle technology for basic biomedical and clinical research. Nanoparticles are already being used clinically to enhance MRI imaging, and drug delivery for cancer patients. Our own research has focused on gene delivery systems for autologous cell transplantation therapy, in which the patient's own cells are transfected with the gene required to correct their condition. In particular, our laboratory and those of others have aimed to optimize magnetofection by developing better nanoparticle coating agents [38, [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [53] [54] [55] . Nanoparticle size is another important parameter but there were few reports addressing this subject [111] . Since cells endocytose MNPs [51, 100, 101] , MNP size has significant implications for transfection efficiency. PEI-MNPs forms magnetoplex, which increased its influence on the magnetic force. Furthermore, MNP size influences cytotoxicity [112] , and more studies on this aspect of MNP technology will be crucial for enhancing transfection efficiencies.
The two research groups reported the important developments in the field of magnetofection. The first is the influence of the oscillating magnetic force on transfection [113, 114] . The second is the use of MNP-heating, and -transfection [15, 16] . The purpose of these studies have increased the efficiency of transfection, and/or induced a fever by oscillating MNPs for hyperthermia. The latter, a combination of MNP-heating and -transfection, was expected to research the efficacy of both hyperthermia and gene delivery. In the future, the studies of magnetofection using the oscillating MNPs could be developed as a novel methodology.
We found that PEI is an excellent cationic polymer for dispersing MNPs and that its water solubility, stability, and low toxicity contribute to enhancing transfection efficiency [95, [115] [116] [117] [118] [119] .
Derivation of iPSCs with the use of non-viral gene delivery using PEI max MNPs should provide a powerful tool for treating diseases such as Alzheimer's, Huntington's, and Parkinson's by autologous cell transplantation. Reprogramming cells requires the action of multiple transcription factors. Our studies demonstrate that MNP-mediated transfection efficiently introduces at least three genes in a single cell. This indicates the feasibility of our system for one-step reprogramming. 
